长期使用糖皮质激素和双膦酸盐的自身免疫病患者中,高耸尖顶型股骨局部反应常进展为完全性和不完全性非典型股骨骨折
该回顾性研究分析12例长期使用双膦酸盐和糖皮质激素的自身免疫病患者共20根股骨,发现局部反应平均高度2.3±0.8 mm,尖顶型占35%;严重型局部反应者高度更高(3.3±0.8 vs 2.1±0.7 mm,p=0.003)且尖顶型更常见(78% vs 27%,p=0.035)。继续使用双膦酸盐者局部反应恶化比例高于停药者(100% vs 29%,p=0.027);停药并换用维生素D补充或特立帕肽治疗可有效改善局部反应形态。
要点
- 局部反应平均高度2.3±0.8 mm,尖顶型占35%。
- 严重型局部反应者高度更高、尖顶型更常见。
- 继续双膦酸盐者局部反应恶化比例高于停药者。
核心结论
- 一旦检测到局部反应,停用双膦酸盐并换用维生素D补充或特立帕肽治疗可有效改善其形态。
- 当局部反应高、呈尖顶型和/或伴有前驱疼痛时,完全性和不完全性非典型股骨骨折风险增加,需考虑对这类患者进行预防性固定。
研究设计与样本
- 回顾性研究,纳入12例使用双膦酸盐和糖皮质激素的自身免疫病患者共20根股骨,均存在股骨局部反应。
- 测量局部反应高度并将形态分为尖顶型、弓型和其他型;局部反应变化分为恶化、无变化和改善。
- 严重型局部反应定义为伴有前驱疼痛、新发完全性非典型股骨骨折或局部反应处有骨折线的不完全性非典型股骨骨折。
主要发现
- 局部反应平均高度为2.3±0.8 mm(范围1.0-3.7 mm),尖顶型占35%。
- 严重型局部反应者局部反应高度显著高于非严重型(3.3±0.8 vs 2.1±0.7 mm,p=0.003),尖顶型比例也更高(78% vs 27%,p=0.035)。
- 7例患者在检测到局部反应后立即停用双膦酸盐,5例继续使用双膦酸盐2年;继续使用者的局部反应恶化比例高于停药者(100% vs 29%,p=0.027)。
- 2年后所有患者均已停用双膦酸盐,无任何患者局部反应进一步恶化。
关键数值与推荐
- 局部反应高度测量值:平均2.3±0.8 mm(范围1.0-3.7 mm)。
- 严重型局部反应者高度3.3±0.8 mm vs 非严重型2.1±0.7 mm(p=0.003)。
- 尖顶型比例:严重型78% vs 非严重型27%(p=0.035)。
- 局部反应恶化比例:继续双膦酸盐者100% vs 停药者29%(p=0.027)。
临床怎么用
- 作者认为,一旦检测到局部反应,停用双膦酸盐并换用维生素D补充或特立帕肽治疗可有效改善其形态。
- 作者认为,当局部反应高、呈尖顶型和/或伴有前驱疼痛时,完全性和不完全性非典型股骨骨折风险增加,需考虑对这类患者进行预防性固定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Once a localized reaction (beaking) was detected, discontinuation of bisphosphonates (BPs) and switching to vitamin D supplementation or teriparatide therapy effectively improved its shape. When the localized reaction was high, of the pointed type, and/or accompanied by prodromal pain, the risks of complete and incomplete atypical femoral fracture increased and consideration of prophylactic fixation for such patients was required. INTRODUCTION: Femoral localized reaction (localized periosteal thickening of the lateral cortex, beaking) is reported to precede atypical femoral fractures (AFFs) and to develop in 8-10% of patients with autoimmune diseases taking BPs and glucocorticoids. The aims of the present study were to retrospectively investigate the shapes of localized reaction to consider how to manage the condition. METHODS: Twenty femora of 12 patients with autoimmune diseases who were on BPs and glucocorticoids exhibited femoral localized reaction. The heights of localized reaction were measured and the shapes classified as pointed, arched, and other. Localized reaction changes were divided into three categories: deterioration, no change, and improvement. A severe form of localized reaction was defined; this was associated with prodromal pain, de novo complete AFF, or incomplete AFF with a fracture line at the localized reaction. RESULTS: The mean height of localized reaction was 2.3 ± 0.8 mm (range, 1.0-3.7 mm) and the pointed type was 35%. Localized reaction was significantly higher (3.3 ± 0.8 vs. 2.1 ± 0.7 mm; p = 0.003) and the pointed type more common (78 vs. 27%; p = 0.035) in those with the severe form of localized reaction. Seven patients with localized reactions discontinued BPs just after localized reaction was detected, but five continued on BPs for 2 years. Localized reaction deterioration was more common in patients who continued than discontinued BPs (100 vs. 29%; p = 0.027). After 2 years, all patients had discontinued BPs and localized reaction did not deteriorate further in any patient. CONCLUSIONS: Once a localized reaction was detected, discontinuation of BPs and switching to vitamin D supplementation or teriparatide therapy effectively improved it. When the localized reaction was high, of the pointed type, and/or accompanied by prodromal pain, the risks of complete and incomplete AFF increased and consideration of prophylactic fixation for such patients was required.
引用
- Sato H, Kondo N, Nakatsue T, et al. High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates. Osteoporos Int. 2017. PMID: 28409215. doi:10.1007/s00198-017-4038-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。